Group 1 - The company, Hansai Aitai-B (03378.HK), plans to globally offer 18.321 million H-shares, with 1.8321 million shares available in Hong Kong and 16.4889 million shares for international offering, subject to reallocation and the exercise of the over-allotment option [1] - The expected pricing range for the shares is HKD 28.00 to HKD 32.00 per share, with the shares anticipated to begin trading on December 23, 2025 [1] - The company specializes in biotechnology with expertise in structural biology, translational medicine, and clinical development, having developed a product pipeline that includes one core product and nine other candidate products [1] Group 2 - The core product, HX009, is a self-developed anti-PD-1/SIRPα dual-function antibody fusion protein, with Phase I clinical trials completed in Australia and China [2] - Currently, three clinical projects for HX009 are ongoing in China, targeting advanced melanoma, relapsed/refractory Epstein-Barr virus-positive non-Hodgkin lymphoma, and advanced biliary tract cancer [2] - The company received approval from the National Medical Products Administration for a combination study of HX009 with trastuzumab for advanced triple-negative breast cancer, with patient recruitment expected to complete by 2026 [2] Group 3 - The company has established cornerstone investment agreements, with cornerstone investors agreeing to subscribe for a total of 2.9178 million shares at the maximum offer price of HKD 32.00 per share [3] - Key cornerstone investors include Fude Resources Investment Holdings Group, Sage Partners Master Fund, and Guotai Junan Securities Investment (Hong Kong) Limited, among others [3] Group 4 - Assuming no over-allotment option is exercised, the company expects to net approximately HKD 496.3 million from the global offering at an indicative offer price of HKD 30.00 per share [4] - The net proceeds are planned to be allocated as follows: approximately 35% for the development of the core product HX009, 33% for the main products HX301 and HX044, 17% for other important product development, 5% for commercialization and business development activities, and 10% for working capital and general corporate purposes [4]

香港聯合交易所有限公司及證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不就因本申請版本全部或任何部分內容而產生或依賴該等內容而引致 的任何損失承擔任何責任。 Hanx Biopharmaceuticals (Wuhan) Co., Ltd. 翰 思 艾 泰 生 物 醫 藥 科 技（ 武 漢 ）股 份 有 限 公 司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）╱證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本。本申請版本內所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即 代表 閣下知悉、接納並向本公司、其獨家保薦人、獨家整體協調人、顧問或包銷團成員表示同意： 於本公司招股章程根據香港法例第32章公司（清盤及雜項條文）條例送呈香港公司註冊處處長登記前，不 會向香港公眾人士提出要約或邀請。倘在適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依 據於香港公司註冊處處長註冊的本公司招股章程作出投資決定。該 ...

香港聯合交易所有限公司及證券及期貨事務監察委員會對本聆訊後資料集的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示概不就因本聆訊後資料集全部或任何部分內容而產生或依賴該等內 容而引致的任何損失承擔任何責任。 Hanx Biopharmaceuticals (Wuhan) Co., Ltd. 翰 思 艾 泰 生 物 醫 藥 科 技（ 武 漢 ）股 份 有 限 公 司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的聆訊後資料集 警告 本聆訊後資料集乃根據香港聯合交易所有限公司（「聯交所」）╱證券及期貨事務監察委員會（「證監會」）的 要求而刊發，僅用作提供資訊予香港公眾人士。 本聆訊後資料集為草擬本。本聆訊後資料集內所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本 文件，即代表 閣下知悉、接納並向本公司、其獨家保薦人、獨家整體協調人、顧問或包銷團成員表示同 意： 於本公司招股章程根據香港法例第32章公司（清盤及雜項條文）條例送呈香港公司註冊處處長登記前，不 會向香港公眾人士提出要約或邀請。倘在適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依 據於香港公司註冊處處長註冊的本公 ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Post Hearing Information Pack, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Post Hearing Information Pack. Post Hearing Information Pack of Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (翰思艾泰生物醫藥科技 (武 漢 )股份有限公司 ) (the "Comp ...

WARNING The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (翰思艾泰生物醫藥科技(武漢)股份有限公司 ) (the "Company") (A joint stock company in ...

Group 1 - The core viewpoint of the article is that Hansai Aitai Biopharmaceutical Technology (Wuhan) Co., Ltd. has submitted its Hong Kong IPO prospectus, which has now expired after six months [1] - The company specializes in structural biology, translational medicine, and clinical development, showcasing its expertise and experience in these fields [2] - Since 2016, the company has been developing an innovative pipeline that includes one core product and nine other candidate products, focusing on oncology and autoimmune markets [2] Group 2 - The pipeline includes three clinical-stage candidates for oncology, namely the core product HX009 and major products HX301 and HX044 [2] - Additionally, there are seven preclinical candidates, which consist of antibody-drug conjugates, bispecific antibodies, and monoclonal antibodies targeting autoimmune and oncology markets [2] - The company has previously developed HX008, which has been transferred to a biopharmaceutical company focused on oncology therapies [2]

Group 1 - The core viewpoint of the article is that Hansai Aitai Biopharmaceutical Technology (Wuhan) Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, with ICBC International as the exclusive sponsor [1] - The company focuses on structural biology, translational medicine, and clinical development, having developed an innovative drug pipeline since 2016, including its core product HX009 and nine other pipeline candidates [1][2] - HX009 is a self-developed PD-1/SIRPα dual-function antibody fusion protein currently undergoing multiple clinical trials in China for treating advanced melanoma, relapsed/refractory EBV-positive non-Hodgkin lymphoma, and advanced biliary cancer [1][2] Group 2 - The company has two main products, HX301 and HX044, with HX301 being a multi-target kinase inhibitor in a Phase II clinical trial for glioblastoma in China, and HX044 being a novel dual-function anti-CTLA-4 antibody SIRPα fusion protein in Phase I/IIa trials for advanced solid tumors in Australia and China [2] - According to a Frost & Sullivan report, HX009 is leading globally in clinical trial progress among similar CD47-targeting bispecific antibodies/dual-function fusion proteins, while HX044 is the only CTLA-4/SIRPα dual-specific antibody/dual-function fusion protein in clinical trials [2] - The company has developed proprietary platforms, VersatiBody and autoRx40, for creating antibody drugs with enhanced therapeutic capabilities, and has received royalties from HX008, a PD-1 monoclonal antibody approved in 2022 [2] Group 3 - As of the fiscal years ending December 31, 2023, and 2024, the company's R&D costs are projected to be RMB 46.7 million and RMB 74.7 million, accounting for 73.0% and 61.8% of total operating expenses, respectively [2] - The company has not yet achieved profitability and continues to invest heavily in R&D activities [2] - The company faces significant risks, including uncertainties in drug development, potential unmet expectations in clinical trial results, and challenges in obtaining regulatory approvals or commercializing its products [3]